Table 1 Patient population baseline characteristics
From: Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients
Characteristic | WBRT | SRS | WBRT+ SRS | Surgery+ SRS | Surgery + WBRT | Surgery + WBRT + SRS | Total |
|---|---|---|---|---|---|---|---|
| Â | (n = 117) | (n = 65) | (n = 48) | (n = 15) | (n = 11) | (n = 19) | (n = 275) |
Age at diagnosis, median (range) | 62 (31-86) | 61 (37-84) | 57.5 (36-79) | 57 (29-72) | 60 (42-80) | 60 (31-86) | 60 (29-86) |
<65 | 61 | 37 | 38 | 13 | 7 | 12 | 168 |
≥65 | 56 | 28 | 10 | 2 | 4 | 7 | 107 |
ECOG-PS | Â | Â | Â | Â | Â | Â | Â |
0 | 1 | 2 | 5 | 1 | 0 | 0 | 9 |
1 | 29 | 19 | 13 | 3 | 1 | 1 | 66 |
2 | 16 | 6 | 4 | 0 | 0 | 3 | 29 |
3 | 4 | 3 | 0 | 0 | 0 | 0 | 7 |
4 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
Unknown | 67 | 35 | 25 | 11 | 10 | 14 | 162 |
Primary Tumor Histology | Â | Â | Â | Â | Â | Â | Â |
NSCLC | 37 | 30 | 22 | 6 | 6 | 11 | 112 |
SCLC | 18 | 5 | 1 | 1 | 2 | 0 | 27 |
Breast | 20 | 8 | 12 | 0 | 0 | 2 | 42 |
Melanoma | 7 | 7 | 3 | 4 | 1 | 3 | 25 |
Renal-cell carcinoma | 5 | 1 | 1 | 2 | 0 | 0 | 9 |
Other | 26 | 9 | 7 | 2 | 0 | 1 | 45 |
Unknown | 4 | 5 | 2 | 0 | 2 | 2 | 15 |
# Brain Metastases | Â | Â | Â | Â | Â | Â | Â |
1 | 34 | 38 | 16 | 10 | 7 | 12 | 117 |
2-4 | 26 | 20 | 16 | 3 | 0 | 6 | 71 |
>4 | 9 | 2 | 7 | 1 | 0 | 0 | 19 |
Unknown | 48 | 5 | 9 | 1 | 4 | 1 | 68 |
Tumor Volume (cm 3 ) | Â | Â | Â | Â | Â | Â | Â |
<2 | 1 | 18 | 8 | 1 | 0 | 2 | 30 |
2-3.9 | 0 | 16 | 8 | 2 | 0 | 3 | 29 |
4-5.9 | 0 | 6 | 5 | 3 | 0 | 1 | 15 |
6-7.9 | 0 | 6 | 9 | 0 | 0 | 2 | 17 |
≥8 | 0 | 10 | 11 | 3 | 0 | 9 | 33 |
NA/Unknown | 116 | 9 | 7 | 6 | 11 | 2 | 151 |